YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Progress demonstrates that BioHarvest's Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solution Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate &…
* BioHarvest Sciences (BHST [https://seekingalpha.com/symbol/BHST]) said [https://seekingalpha.com/pr/20666913-bioharvest-sciences-announces-share-repurchase-program]its board has authorized a share repurchase program under a normal course…
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today…
BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary - Moby Strategic Shift and Operational Performance Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you…
BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound Proactive uses images sourced from Shutterstock BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported higher second-quarter revenue as the pla…
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring i…
* BioHarvest Sciences press release [https://seekingalpha.com/filing/309934017] (BHST [https://seekingalpha.com/symbol/BHST]): Q2 GAAP EPS of -$0.17 misses by $0.05. * Revenue of $8.84M (+3.8% Y/Y) misses by $0.61M. MORE ON BIOHARVEST SCIE…
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago. These figures are adjusted for non-recurring items…
4:15pm: Apple surges, inflation cools Stocks finished higher on Wednesday as another softer-than-expected inflation report reinforced expectations that the Federal Reserve could keep interest rates on hold in the months ahead. The Dow Jone…
Image source: The Motley Fool. DATE Thursday, May 14, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Zaki Rakib Chief Operating Officer — Bar Dichter Co-Founder, Board Director — Ilan Sobel Need a quote from a Motley Fool an…
Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories. Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18…
Key Points Interested in BioHarvest Sciences Inc.? Here are five stocks we like better. BioHarvest Sciences reported first-quarter revenue of $8.5 million, up 8% year over year, and kept its 2026 guidance unchanged for both the D2C and CDM…
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the company advanced several contract development and manufacturing organization (CDMO) projects and expanded its direct-to-consumer wellness b…
BioHarvest Sciences wins $1.2M fragrance contract Proactive uses images sourced from Shutterstock BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has secured a $1.2 million Stage 2 contract to develop a rare scent-producing plant compound…
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurri…
BioHarvest Sciences names co-founder Rakib as CEO in leadership transition Proactive uses images sourced from Shutterstock BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has appointed co-founder Dr Zaki Rakib as CEO,…
The United States market remained flat over the last week but has experienced a significant 30% increase over the past year, with earnings forecasted to grow by 16% annually. In such an environment, identifying stocks that are trading belo…
Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings expected to grow by 16% per annum in the coming years. In this environment, identifying stocks that may be trading at an es…
Over the last 7 days, the United States market has remained flat, yet it has experienced a significant 30% increase over the past year with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be tra…
Over the last 7 days, the United States market has remained flat, yet it has experienced a significant 30% increase over the past year with earnings forecasted to grow by 16% annually. In this environment, identifying stocks that might be…
The United States market has remained flat over the past week, yet it has experienced a notable 30% rise over the last year, with earnings projected to grow by 16% annually in the coming years. In this context, identifying stocks that are…
The United States market has remained flat over the past week but has seen a significant increase of 30% over the past year, with earnings projected to grow by 16% annually in the coming years. In this context, identifying stocks that may…
Over the last 7 days, the United States market has risen by 1.7%, contributing to a remarkable 34% increase over the past year, with earnings anticipated to grow by 16% annually in the coming years. In such a thriving environment, identify…
Over the last 7 days, the United States market has risen by 1.7%, contributing to a notable 34% climb over the past year, with earnings anticipated to grow by 16% annually in the coming years. In this environment of robust growth, identify…
Over the last 7 days, the United States market has risen by 1.3% and is up 35% over the past year, with earnings expected to grow by 16% annually in the coming years. In this environment of robust growth, identifying stocks that are potent…
The market in the United States has shown robust performance, climbing 4.0% in the last 7 days and achieving a 39% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, id…
The United States market has experienced a robust performance, rising 4.0% over the last week and 39% over the past year, with earnings anticipated to grow by 16% annually. In this thriving environment, identifying stocks that may be price…
The United States market has shown robust performance, with a 3.4% increase over the last week and a remarkable 35% rise over the past year, while earnings are projected to grow by 16% annually. In such an environment, identifying stocks t…
The United States market has shown robust growth, rising 3.4% over the last week and climbing 35% in the past year, with earnings projected to increase by 16% annually. In such a thriving environment, identifying undervalued stocks can pre…
BioHarvest Sciences Inc. Common Stock Q4 2025 Earnings Call Summary - Moby Strategic Execution and Operational Context Transitioned to a 'two-lens' management framework to optimize capital allocation between the maturing Direct-to-Consumer…
BioHarvest Sciences logo Key Points Q4 revenue $9.1 million (up 25% YoY) and full-year revenue of $34.5 million (up 37%) with gross margin near 59%; adjusted EBITDA was positive $0.5 million and cash rose to $23 million from $2.4 million a…
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring it…
BioHarvest Sciences achieves revenue gains and margin expansion, narrows losses in 2025 Proactive uses images sourced from Shutterstock BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has reported its financial results for the fourth quart…
The following companies are expected to report earnings after hours on 03/31/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Nike, Inc. (NKE)is reporting for the quarter ending February 28, 2026. The shoes…
BioHarvest Sciences advances sustainable fragrance production with rare plant breakthrough Proactive uses images sourced from Shutterstock BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has completed the first stage of a…
BioHarvest appoints former Israeli health chief Hezi Levy to board Proactive uses images sourced from Shutterstock BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday that it has appointed former Israeli health ministry chief…